Back to search

Article

A novel single TCR gamma chain fused with antibody-based binding domain facilitates T cell cytotoxicity for potent anti-tumor response without forming TCR-CD3 complex

2022-05-27

Abstract excerpt

Chimeric antigen receptor (CAR)-T cells have shown potent clinical efficacy in the treatment of hematopoietic malignancies. However, much less has been achieved in solid tumors, in part due to the CAR-T cell exhaustion caused by inhibitory molecules in the tumor microenvironment. Given that PD-L1 is widely expressed in various tumor types and the PD1/PD-L1 axis plays a pivotal role in T cell exhaustion, we develop...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
279113f6-4ebb-56ac-b5d3-f9066874f509
DOI
10.21203/rs.3.rs-1602710/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
A novel single TCR gamma chain fused with antibody-based binding domain facilitates T cell cytotoxicity for potent anti-tumor response without forming TCR-CD3 complexDOI 10.21203/rs.3.rs-1602710/v1
Select a neighboring publication to make it the new centre.